1 day ago
3
David Jagielski, CPA, The Motley Fool
Mon, March 2, 2026 astatine 11:20 AM CST 3 min read
For years, UnitedHealth Group (NYSE: UNH) banal has been a terrific maturation investment. In fact, it looked unstoppable. Not lone did it repeatedly turn its dividend, but the banal was amassing immoderate outstanding results on the way. It was looking similar the eventual healthcare banal to ain for the agelong term.
But things person changed drastically for UnitedHealth Group wrong conscionable the past 12 months. Concerns astir rising costs and investigations into its billing practices person importantly weighed connected its valuation. During that clip frame, the banal has fallen by 37%. It finished past week astatine a terms of astir $293, which is down importantly from its 52-week precocious of much than $606.
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »
This year, it's already down much than 10%. And whether the wellness security elephantine is capable to crook things astir could hinge connected 1 precise important metric.
The cardinal metric that investors and analysts often absorption connected for UnitedHealth Group is its aesculapian attraction ratio. This represents however overmuch of the premiums the institution collects are spent connected aesculapian attraction for its members. The higher the ratio is, the worse the prospects for profitability are.
For UnitedHealth, the ratio has been rising successful caller years. In 2025, the aesculapian attraction ratio for the afloat twelvemonth was 89.1%, up from 85.5% successful the erstwhile year, which was already higher than the 83.2% it averaged successful 2023. Without a important diminution and betterment successful that rate, investors whitethorn beryllium acrophobic astir the quality of UnitedHealth to turn its profits. The institution blames the summation connected a fig of factors, including Medicare backing reductions and "accelerating aesculapian outgo trends." Its quality to support costs down volition beryllium important for the concern to amusement investors it's moving successful the close direction.
UnitedHealth banal is simply a overmuch riskier-looking banal than it has been successful the past. It's nary longer trading astatine a multi-year low, but by nary means is it taking disconnected and looking similar it'll retrieve anytime soon from its monolithic sell-off. There are immoderate large clouds hovering implicit the banal these days, including however ongoing investigations into its billing practices mightiness interaction its aboriginal growth, and if it tin find capable efficiencies and opportunities to bring down its costs and amended margins.
English (CA) · 
English (US) · 
Spanish (MX) ·